Evidence mapPaperPMID 30836637Full record

Trial reportNutrients2019

Similar Weight Loss Induces Greater Improvements in Insulin Sensitivity and Liver Function among Individuals with NAFLD Compared to Individuals without NAFLD.

Ruth Schübel, Tobias Nonnenmacher, Disorn Sookthai, Sandra Gonzalez Maldonado, Solomon A Sowah, Oyunbileg von Stackelberg, Christopher L Schlett, Mirja Grafetstätter, Diana Nabers, Theron Johnson and 6 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06348628 (Motivational Interviewing for Weight Loss in the Management of Non Alcoholic Fatty Liver Disease - A Randomized Controlled Trial), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06348628 nacompletednot on this mapstarted 2022, after this paper: background citation

Motivational Interviewing for Weight Loss in the Management of Non Alcoholic Fatty Liver Disease - A Randomized Controlled Trial

TypeinterventionalSponsorMadunil Anuk NiriellaRan2022 to 2025Enrolled231ConditionsNon-Alcoholic Fatty Liver DiseaseArmsMotivational Interview, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Ruth SchübelGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. Ruth.Schuebel@med.uni-heidelberg.de.
Tobias NonnenmacherHeidelberg University Hospital, Diagnostic and Interventional Radiology, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. tno144@googlemail.com.
Disorn SookthaiGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. d.sookthai@dkfz-heidelberg.de.
Sandra Gonzalez MaldonadoGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. s.gonzalezmaldonado@dkfz-heidelberg.de.
Solomon A SowahGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. s.sowah@dkfz-heidelberg.de.
Oyunbileg von StackelbergHeidelberg University Hospital, Diagnostic and Interventional Radiology, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. oyunbileg.stackelberg@med.uni-heidelberg.de.
Christopher L SchlettHeidelberg University Hospital, Diagnostic and Interventional Radiology, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. Christopher.Schlett@med.uni-heidelberg.de.
Mirja GrafetstätterGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. mi.graf@dkfz-heidelberg.de.
Diana NabersGerman Cancer Research Center (DKFZ), Division of Medical and Biological Informatics, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. d.nabers@dkfz-heidelberg.de.
Theron JohnsonGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. t.johnson@Dkfz-Heidelberg.de.ORCID 0000-0003-4850-282X
Romy KirstenNational Center for Tumor Diseases (NCT), Liquid Biobank, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. romy.kirsten@nct-heidelberg.de.
Cornelia M UlrichHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112-5550, USA. neli@hci.utah.edu.ORCID 0000-0001-7641-059X
Rudolf KaaksGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. r.kaaks@Dkfz-Heidelberg.de.
Hans-Ulrich KauczorHeidelberg University Hospital, Diagnostic and Interventional Radiology, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. Hans-Ulrich.Kauczor@med.uni-heidelberg.de.
Tilman KühnGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. t.kuehn@dkfz-heidelberg.de.
Johanna NattenmüllerHeidelberg University Hospital, Diagnostic and Interventional Radiology, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. Johanna.nattenmueller@med.uni-heidelberg.de.
German Cancer Research Center · DEHeidelberg University · DENational Center for Tumor Diseases · DEUniversity of Utah · US

Funding

Helmholtz Association Cross-Program Topic: Metabolic DysfunctionHuntsman Cancer Foundation Huntsman Cancer FoundationNational Cancer Institute R01 CA189184, R01 CA207371, U01 CA206110, and P30 CA042014Stiftung zur Förderung der Erforschung der Zivilisationserkrankungen Stiftung zur Förderung der Erforschung der Zivilisationserkrankungen
6 · The paper itself

Abstract

backgroundPreliminary evidence suggests that weight loss among obese has differential metabolic effects depending on the presence of non-alcoholic fatty liver disease (NAFLD). We assessed whether NAFLD predisposes to differential changes in liver fat content, liver function, and metabolic parameters upon diet-induced weight loss in a 50-week intervention trial.

methods143 overweight and obese non-smokers underwent a 12-week dietary intervention and a 38-week follow-up. Diet-induced changes in anthropometric measures, circulating biomarkers, and magnetic resonance (MR)-derived liver fat content and adipose tissue volumes were evaluated by mixed linear models stratifying by NAFLD at baseline.

resultsThe prevalence of NAFLD at baseline was 52%. Diet-induced weight loss after 12 (NAFLD: 4.8 ± 0.5%, No NAFLD: 5.1 ± 0.5%) and 50 weeks (NAFLD: 3.5 ± 0.7%, No NAFLD: 3.5 ± 0.9%) was similar in both groups, while the decrease in liver fat was significantly greater in the NAFLD group (week 12: 32.9 ± 9.5% vs. 6.3 ± 4.0%; week 50: 23.3 ± 4.4% vs. 5.0 ± 4.2%). Decreases in biomarkers of liver dysfunction (GGT, ALT, AST) and HOMA IR were also significantly greater in the NAFLD group. Other metabolic parameters showed no significant differences.

conclusionOur data suggest that individuals with NAFLD show greater improvements of liver function and insulin sensitivity after moderate diet-induced weight loss than individuals without NAFLD.

Indexed as

AdultBiomarkersDiet, ReducingFemaleHumansInsulin ResistanceLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseObesityTreatment OutcomeWeight LossBiomarkersinsulin sensitivityliver functionmagnetic resonance imagingnon-alcoholic fatty liver diseaseobesity

Identifiers

PMID30836637
PMCPMC6471668
OpenAlexW2920366186

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.